spacer
home > ict > spring 2008 > expect the unexpected
PUBLICATIONS
International Clinical Trials

Expect the Unexpected

The centralised independent reviewing process improves the skills and knowledge of the reviewers – providing important benefits for the healthcare community, the pharmaceutical industry and patients, explains Oliver Bohnsack and Manuela Lesch of Perceptive Informatics, a PAREXEL International company

Advanced medical imaging technologies play a vital role in many pivotal clinical trials today, providing primary and surrogate endpoints to support the safety and efficacy of a wide variety of biopharmaceutical products. With the dramatic improvements in these technologies in recent years, clinical study sponsors increasingly rely on imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, and positron emission tomography (PET) to validate novel therapies and decrease the time and cost of clinical development.

An essential adjunct to the growing importance of medical imaging technology in clinical trials is the need for independent reviews of the study images. The initial reviews of medical imaging are performed by site-based radiologists who are directly involved in the study, therefore regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) require additional reviews by independent radiologists to validate the results.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Oliver Bohnsack is a Medical Director based in the Berlin office of Perceptive Informatics, the technology business of PAREXEL. In this role, he has led the imaging component of multiple studies, from both a medical and a scientific approach. Oliver is a Board Certified Radiologist and has broad clinical radiology experience in Germany and the US, as well as at various companies in the biopharmaceutical industry. He holds a PhD in Radiology from the University of Munich and a Masters in Business Administration in Health Care Management from the University of California, Irvine. Oliver has presented at several international conferences on the topic of medical imaging in clinical trials, and particularly regarding the utilisation of standardised review criteria.

Manuela Lesch is a Medical Research Scientist based in the Berlin office of Perceptive Informatics. Manuela develops study-specific documents and guidelines, and assists in reviewer management. She supports companies with charter development, including presenting at investigator meetings and conferences. Manuela also has expertise in overseeing imaging operations of a range of therapeutic studies, including central nervous system (CNS) studies. A Radiologic Technologist by training, Manuela has several years of experience in multiple imaging modalities, including conventional radiology, CT, MRI, nuclear medicine and radiation therapy, and has also specialised in neuroradiology imaging.

spacer
Oliver Bohnsack
spacer
spacer
spacer
Manuela Lesch
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI expert forecasts ‘huge growth in Middle East manufacturing with Europe a medium-term target’

CPhI Middle East & Africa (CPhI MEA) expert Madhukar Tanna, Chief Executive Officer of Pharmax, a United Arab Emirates (UAE) based branded generic manufacturer, says favourable conditions in the UAE are resulting in a boom of pharmaceutical manufacturing throughout the region. Government incentive schemes to increase domestic production, coupled with a brand friendly environment and rising healthcare needs is fuelling surging demand – with many new companies and plants launching in the last two years alone.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement